Journal
Journal of Clinical Investigation
Publication Date
9-2-2025
Volume
135
Issue
17
First Page
e188530
Document Type
Open Access Publication
DOI
10.1172/JCI188530
Rights and Permissions
Krueger JG, Sarkar MK, Lebwohl MG, Morita A, Gordon K, Bogle R, Cole C, Coon A, Langley RG, Warren RB, Mostaghimi A, Strober B, Burden AD, Zheng M, Mangold AR, Anadkat MJ, Barker JN, Merola JF, Tsoi LC, Tang M, Becker K, Delic D, Thoma C, Gudjonsson JE. Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 Jul 1;135(17):e188530. doi: 10.1172/JCI188530. © 2025, Krueger et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
Recommended Citation
Krueger, James G.; Anadkat, Milan J.; and et al., "Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares." Journal of Clinical Investigation. 135, 17. e188530 (2025).
https://digitalcommons.wustl.edu/oa_4/5662
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
